<DOC>
	<DOCNO>NCT00718601</DOCNO>
	<brief_summary>The purpose study determine safety maximum tolerate dose ( MTD ) GRN163L Velcade without Decadron administer patient refractory relapse multiple myeloma .</brief_summary>
	<brief_title>Safety Dose Study GRN163L Velcade Treat Patients With Refractory Relapsed Myeloma</brief_title>
	<detailed_description>GRN163L telomerase template antagonist vitro vivo activity variety tumor model system . Telomerase enzyme active primarily tumor cell crucial indefinite growth tumor cell . Inhibition telomerase may result antineoplastic effect .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Confirmed diagnosis multiple myeloma ( either secretory nonsecretory disease ) Relapsed refractory disease ECOG performance status 02 Adequate hepatic/renal function platelet count If previously treat anthracycline , anthracenedione , trastuzumab , must leave ventricular ejection fraction &gt; 50 % Fully recover previous cancer treatment and/or major surgery Prior allogeneic bone marrow transplant , include syngeneic transplant Bone marrow transplant within 12 week prior study Known intracranial disease epidural disease Inability tolerate Velcade Inability tolerate Decadron Prior malignancy ( within last 3 year ) Clinically significant cardiovascular disease condition Active chronically recurrent bleeding ( eg , active peptic ulcer disease Prolongation PT aPTT &gt; ULN fibrinogen &lt; LLN Clinically relevant active infection Serious comorbid medical condition , include cirrhosis chronic obstructive chronic restrictive pulmonary disease Any cancer therapy within 4 week prior study , nitrosourea within 6 week prior study Investigational therapy within 4 week prior study Antiplatelet therapy within 2 week prior study , low dose aspirin prophylaxis therapy low dose heparin administration management IV access device Radiation therapy within 4 week prior study Major surgery within 4 week prior study Active autoimmune disease require immunosuppressive therapy Known positive serology HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Myeloma</keyword>
	<keyword>Multiple Myeloma</keyword>
	<keyword>Relapsed Multiple Myeloma</keyword>
	<keyword>Refractory Multiple Myeloma</keyword>
	<keyword>Relapsed Refractory Multiple Myeloma</keyword>
</DOC>